secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vaxcyte, Inc. (PCVX)
CIK:        0001649094
Form:       8-K
Filed at:   2022-10-24T23:59:59+00:00
Accession:  0001193125-22-267147
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vaxcyte VAX-24 Phase 1/2 meets all endpoints; 2.2mcg dose advances to Phase 3
-----------------------------------------------------------------------------

- VAX-24 safety profile similar to Prevnar 20 at all doses; no related SAEs or chronic illnesses.
- All 24 serotypes met/exceeded regulatory immunogenicity standards at 2.2mcg dose.
- Of 20 serotypes common with PCV20, 16 showed higher OPA immune responses; 4 reached statistical significance.
- All 4 unique serotypes (2, 9N, 17F, 20B) exceeded standard superiority criteria at all doses.
- Milestones: Phase 3 adult data expected 2025; infant Phase 2 initiation in H1 2023; VAX-XP (31-valent) IND in H2 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1649094/000119312522267147/0001193125-22-267147-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1649094/000119312522267147/d413834d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-267147

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer